Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Radium-223 mechanism of action: implications for use in treatment combinations.

Morris MJ, Corey E, Guise TA, Gulley JL, Kevin Kelly W, Quinn DI, Scholz A, Sgouros G.

Nat Rev Urol. 2019 Dec;16(12):745-756. doi: 10.1038/s41585-019-0251-x. Epub 2019 Nov 11. Review.

PMID:
31712765
2.

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, Alhoniemi EJ, Laine SK, Corey E, Mumberg D, Ziegelbauer K, Käkönen SM, Halleen JM, Vessella RL, Scholz A.

Clin Cancer Res. 2017 Aug 1;23(15):4335-4346. doi: 10.1158/1078-0432.CCR-16-2955. Epub 2017 Mar 31.

3.

Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.

Takalkar A, Adams S, Subbiah V.

Exp Hematol Oncol. 2014 Sep 8;3:23. doi: 10.1186/2162-3619-3-23. eCollection 2014.

4.

Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.

McGann S, Horton ER.

Ann Pharmacother. 2015 Apr;49(4):469-76. doi: 10.1177/1060028014565444. Epub 2015 Jan 8. Review.

PMID:
25573268
5.

Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.

Ryan CJ, Saylor PJ, Everly JJ, Sartor O.

Oncologist. 2014 Oct;19(10):1012-8. doi: 10.1634/theoncologist.2013-0472. Epub 2014 Sep 17. Review.

6.

Treatment of Metastatic Bone Disease and the Emerging Role of Radium-223.

Coleman R.

Semin Nucl Med. 2016 Mar;46(2):99-104. doi: 10.1053/j.semnuclmed.2015.10.012. Review.

PMID:
26897713
7.

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.

Vogelzang NJ.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):809-819. doi: 10.1080/17512433.2017.1345624. Epub 2017 Jul 3. Review.

PMID:
28649893
8.

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.

Humm JL, Sartor O, Parker C, Bruland OS, Macklis R.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):898-906. doi: 10.1016/j.ijrobp.2014.12.061. Review.

PMID:
25832684
9.

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M.

Eur J Nucl Med Mol Imaging. 2018 May;45(5):824-845. doi: 10.1007/s00259-017-3900-4. Epub 2017 Dec 12.

PMID:
29234845
10.

Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.

Gallicchio R, Mastrangelo PA, Nardelli A, Mainenti PP, Colasurdo AP, Landriscina M, Guglielmi G, Storto G.

Tumori. 2019 Oct;105(5):367-377. doi: 10.1177/0300891619851376. Epub 2019 May 16. Review.

PMID:
31096849
11.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O'Bryan-Tear CG, Shan M, Bruland ØS, Parker C.

Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13.

PMID:
24836273
12.

Radium 223 dichloride for prostate cancer treatment.

Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houédé N.

Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. doi: 10.2147/DDDT.S122417. eCollection 2017. Review.

13.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
14.

Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease.

Harrison MR, Wong TZ, Armstrong AJ, George DJ.

Cancer Manag Res. 2013;5:1-14. doi: 10.2147/CMAR.S25537. Epub 2013 Jan 8.

15.

Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.

Nilsson S.

Expert Opin Drug Saf. 2015 Jul;14(7):1127-36. doi: 10.1517/14740338.2015.1045874. Epub 2015 May 28.

PMID:
26022669
16.

Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.

Picciotto M, Franchina T, Russo A, Ricciardi GRR, Provazza G, Sava S, Baldari S, Caffo O, Adamo V.

Expert Opin Pharmacother. 2017 Jun;18(9):899-908. doi: 10.1080/14656566.2017.1323875. Epub 2017 May 8. Review.

PMID:
28449621
17.
18.

Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.

Targeted Alpha Therapy Working Group, Parker C, Lewington V, Shore N, Kratochwil C, Levy M, Lindén O, Noordzij W, Park J, Saad F.

JAMA Oncol. 2018 Dec 1;4(12):1765-1772. doi: 10.1001/jamaoncol.2018.4044. Review.

PMID:
30326033
19.

Current perspectives on bone metastases in castrate-resistant prostate cancer.

Logothetis C, Morris MJ, Den R, Coleman RE.

Cancer Metastasis Rev. 2018 Mar;37(1):189-196. doi: 10.1007/s10555-017-9719-4. Review.

20.

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

Rodriguez-Vida A, Torregrosa MD, Pinto Á, Climent MÁ, Olmos D, Carles J.

Clin Transl Oncol. 2018 Jun;20(6):679-686. doi: 10.1007/s12094-017-1785-0. Epub 2017 Nov 2. Review.

PMID:
29098556

Supplemental Content

Support Center